PuSH - Publikationsserver des Helmholtz Zentrums München: Direct Reprogramming of Somatic Cells into Induced Neuronal Cells: Where We Are and Where We Want to Go.

Informationen

Hinweise zu Qualitätskriterien von Zeitschriften

Open-Access-Richtlinie der Helmholtz-Gemeinschaft 2016

CC Licencences

Metriken für Publikationen

Navigation

Startseite

English

Recherche

Erweiterte Suche

Durchblättern nach ...

... HMGU-Autoren/Konsortien

... Organisationsstruktur

... Zeitschriften

... Publikationstypen

... Forschungsdaten

... Arbeitsgruppen

... Erscheinungsjahr

Publikationen im Überblick

Statistik

HGF Fortschrittsbericht

OA Publikationen

Eintragen

Neue Publikation eintragen

Neue Publikation holen aus...

...EVA

Fehlende Publikation melden

Highlights

Suche

Hilfe & Kontakt

Ansprechpartner

Hilfe

Datenschutz

Helmholtz Open Science

Bibliometrische Indikatoren

SHERPA/RoMEO

DOAJ

Export:

Text

Endnote (RIS) BIB

BibTeX

Masserdotti, G. ; Berninger, B.*

Direct Reprogramming of Somatic Cells into Induced Neuronal Cells: Where We Are and Where We Want to Go.

In:. 2015. 175-195 (Stem Cell Biology and Regenerative Medicine ; Part F4879)

DOI

Abstract
Metriken
Zusatzinfos

Direct reprogramming of somatic cells has emerged as a novel strategy to generate neurons, including those of human origin. The method provides enormous potential for studying the mechanisms directing neuronal differentiation, the modeling of neurodegenerative diseases, and the development of potential novel approaches for brain repair. In this chapter, we briefly trace the history of reprogramming, as well as the strategies employed to date for converting different types of somatic cells, including fibroblasts, hepatocytes, astrocytes, and pericytes into induced neuronal cells of different subtype identity. Reprogramming involves particular emphasis on transcriptional and posttranscriptional mechanisms, which include an arsenal of transcription factors, including among others the pro-neural genes Ascl1 and Neurog2, noncoding RNAs such as miRNA 124 and miRNA 9/9*, and epigenetic modifiers such as the brahma-associated factors (BAF) complex summarized in Fig. 1. Finally, we discuss upcoming challenges to further improve this technology and the promises it holds for our understanding and treatment of currently incurable diseases.

Altmetric